Oslo, Norway, November 7, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete
Fredriksen, will present and host 1x1 meetings at two upcoming investor
conferences in November.

Presentation Details

Credit Suisse Annual Healthcare Conference
Date: Tuesday, November 8, 2022 

Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022

Slides of both presentations can be accessed in the Investors section of the
Company's website here:
https://nykode.com/investors/financial-reports-and-presentations/
A live and archived webcast of the Jefferies presentation will also be
available.   


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase 2 trial
for the treatment of cervical cancer